Aktien Sensor

Illumina’s Board of Directors has undergone changes, with Keith Meister joining as a new member and Scott Gottlieb becoming non-executive Chair, amidst a period of leadership transition.

Illumina has partnered with Broad Clinical Labs to develop scalable single-cell sequencing technologies, aiming to create a 5 billion cell atlas within three years.

Illumina’s stock price has hit a new 1-year low, but the company is counting on its new spatial transcriptomics technology to drive a turnaround and reverse its fortunes.

Illumina’s stock price has plummeted after an analyst downgrade, sparking concerns about the company’s business model and growth prospects.